Vaccine demonstrates benefit in delaying cancer relapse
Data from the Phase I trial showed that the cancer…
Data from the Phase I trial showed that the cancer vaccine offered an 86 percent reduction in the risk of relapse or death in pancreatic and colorectal cancers.